quantities of soluble capsular polysaccharide extrude from bacteria after overnight growth. The reduction in capsule expression caused by salicylate largely affected the soluble, cell-free fraction. Purified capsular polysaccharide was shown to retard the opsonophagocytosis of salicylate-treated bacteria in a concentrationdependent manner. However, extensive washing of encapsulated bacteria to remove loosely attached capsular material did not significantly enhance opsonophagocytosis. In conclusion, cell-free capsule and cell-associated capsule are antiphagocytic; both act to neutralize K-specific antibodies by binding or concealment. Salicylatemediated inhibition of capsule expression, particularly of the cell-free fraction, improved K-specific opsonization dramatically.
Encapsulated gram-negative bacteria, such as Kiebsiella pneumoniae, are among the leading causes of morbidity and mortality in the hospital environment (16) . An important characteristic of K pneumoniae growth is the production of capsular polysaccharide (CPS). A thick CPS layer, referred to as a capsule, envelops these bacteria and thwarts protective host defenses (20, 22, 25, 26) . Encapsulated K pneumoniae also produces large quantities of cell-free CPS (12) , which is aggregated with toxic lipopolysaccharide (LPS) and contributes to pathogenicity (1, 11, 21) . Circulating, cell-free CPS may also bind and neutralize antibodies that would otherwise attach to and opsonize bacteria (5, 18) .
The production of opsonizing antibodies is an important aspect of immunity to K pneumoniae. In vitro analysis has identified antibodies to CPS (K-specific antibodies) as important opsonins for phagocytic uptake (19) . Thus, vaccine development for encapsulated bacteria has emphasized capsular (K-specific) antigens (3, 6 from this vaccine for passive administration and has shown promise in combatting K pneumoniae infections (3, 4) .
For K pneumoniae and related bacteria, the quantity of CPS made is directly related to virulence (8, 11, 14) . Salicylate has been used in vitro to reduce CPS expression by several serotypes of K pneumoniae (10) . It was shown recently that the inhibition of K pneumoniae capsule expression with salicylate enhanced the phagocytic uptake of an O1:K2 strain, especially in the presence of antiserum raised in rabbits against homologous, formalinized whole cells (9) . This report evaluates the opsonic potential of K-specific antibodies against a number of K pneumoniae serotypes after capsule reduction. (17) . CPS was measured by uronic acid determinations (2) . Total CPS was measured after mild, quantitative extraction of bacteria with Zwittergent 3-14 (Calbiochem, La Jolla, Calif.) in citric acid (7, 10) .
MATERIALS AND METHODS
Opsonophagocytosis. The growth of bacteria with or without salicylate treatment and the purification of human polymorphonuclear leukocytes (PMNL) have been described previously (9 Antisera. Serotype-specific, polyclonal antisera were raised in rabbits with formalin-treated, whole-cell encapsulated bacteria (13) . K66 antiserum was a gift from Juan M. Tomlas. Nosocuman, a human intravenous immunoglobulin (IVIG) preparation, enriched in antibodies to the Klebsiella K2 CPS, was used both for in vivo studies and for in vitro studies.
Immunofluorescence. Smears were prepared from opsonophagocytic mixtures to demonstrate rabbit K2 antibodies bound to O1:K2. Goat anti-rabbit immunoglobulin G (IgG) conjugated with rhodamine (Sigma), diluted 1:100, was incubated with smears for 30 min at 37°C and examined and photographed by using a Labphot microscope with episcopic fluorescence and Microflex AFX photographic attachments (Nikon Corp.).
RESULTS
The reduced expression of capsule by all K pneumoniae serotypes was achieved by culturing bacteria in the presence of salicylate. Overnight growth in defined medium containing 2.5 mM salicylate reduced CPS expression by 70 to 80% for all strains (10) . In the presence of fresh complement, but in the absence of specific antisera, salicylate treatment increased the %P and the PI only marginally. The results with K-specific antiserum as the opsonin are shown in Fig. 1 An understanding of how decapsulation enhances K-specific opsonophagocytosis may lie in the nature of antibody attachment. It is widely held that bacteria neutralize anticapsular antibodies by producing large quantities of cell-free CPS. Loosely adherent CPS that detaches from bacteria (antigen sloughing) may bind to an opsonic antibody, thus making it unavailable to promote phagocytosis. The influence of antigen sloughing was assessed by thorough removal of loosely attached CPS from bacteria. Three washes of fully encapsulated O1:K2 reduced the quantity of cell-free CPS in samples by several orders of magnitude, as summarized in Table 1 . However, when washed cells were immediately placed into phagocytic assays, the %P and PI in the presence of K-specific antibody increased only slightly. Thus, extensive washing of bacteria to remove cell-free capsule and loosely attached capsule had little influence on the poor opsonization of fully encapsulated bacteria with K-specific antibodies. Compare this with the extensive opsonophagocytosis of O1:K2 pretreated with 1 mM salicylate, which was used as a positive control (Table 1) .
Salicylate also had a significant effect on the proportion of CPS that became cell free during culture. Overnight cultures of K pneumoniae O1:K2 contained large amounts of cell-free capsular material, which fractionated into the supernatant upon centrifugation. The influence of salicylate concentration on overall CPS production and capsule shedding from serotype O1:K2 is shown in Fig. 3 . Cultures showed salicylate concentration-dependent decreases in both cell-associated CPS and cell-free CPS. However, with increasing amounts of salicylate, there was a disproportionately greater decrease in cell-free CPS. At O1:K2 bacteria in phagocytic assays. Added CPS produced a concentration-dependent decrease in %P for decapsulated O1:K2 in the presence of PMNL and K-specific rabbit polyclonal antiserum diluted 1:40. The %P was reduced by 23% ± 15%, 73% ± 29%, and 97% ± 5% with 0.025, 0.25, and 2.5 ,ug of added CPS per ml, respectively. The 50% inhibitory concentration of CPS was 0.145 ,ugIml. Immunofluorescence microscopy showed that even at 2.5 ,ug of added CPS per ml, K-specific antibodies attached in apparently large amounts to bacteria, as illustrated in Fig. 4a , yet virtually no phagocytosis was observed. In Fig. 4b , K-specific antibodies are shown attached to fully encapsulated O1:K2 bacteria which are bound to PMNL. Though the intensity of fluorescence was high, again no phagocytosis was observed.
DISCUSSION
Promoting phagocytosis with decapsulating agents represents a novel approach to immunotherapy as well as a novel form of immune modulation. It is widely assumed that Kspecific antibodies can be neutralized and rendered nonfunctional by copious production of CPS. If copious capsule production and sloughing play an important role in pathogenesis, then salicylate may curtail this virulence parameter and allow K-specific opsonophagocytosis to occur efficiently.
The potential importance of cell-free CPS in pathogenicity warranted a closer look at the conditions that influence its production. Several investigators (11, 12, 14) have observed that cell-free CPS elaborated by K pneumoniae increases in proportion to the size of the cell-associated capsule. The shedding of capsule is influenced by a number of factors, including pH and cation content (7, 23) . It is now evident that salicylate diminishes the sloughing of cell-free CPS to a disproportionately greater degree than expected. The effects of salicylate on pH or chelation of cations could possibly affect the degree of sloughing. Since multivalent cations can act to stabilize capsule structures, copious capsule production can act as a cation sink, thus depleting the "cement" that keeps the capsule together.
By limiting the expression of both cell-associated CPS and cell-free CPS, salicylate rendered bacteria susceptible to phagocytosis in the presence of anticapsular antibodies. Our evidence indicates that even the smallest amount of cell-free CPS carried over from sample preparation can inhibit opsonophagocytosis. The quantity of cell-free CPS in phagocytic assays after one wash of fully encapsulated O1:K2 (120 ng/ml; Table 1 ) approximated the 50% inhibitory concentration for K2 CPS on anti-K2 opsonization (145 ng/ml). Thus, in the standard phagocytosis procedure, enough cell-free CPS is carried over after the preparation of bacteria to inhibit opsonophagocytosis by nearly 50%. However, a more thorough washing of encapsulated O1:K2 did not enhance opsonophagocytosis to any great extent. Though much antibody was bound to the capsule, as seen by immunofluorescence, such attachment did not promote phagocytosis. The nature of antibody attachment in general suggested a concentration gradient, whereby most of the antibody bound to proximal sites within the capsule. A similar immunofluorescence pattern with K-specific antibodies has been reported previously for this serotype (24) .
Since CPS is exposed on the surface of encapsulated K pneumoniae, it is not immediately apparent why the inhibition of CPS enhances opsonization by anticapsular antibodies. The data presented here point to at least three aspects of capsulemediated resistance to K-specific phagocytosis: (i) neutralization of antibody by cell-free CPS, (ii) blocking of phagocytic receptors on PMNL by immune complexes of cell-free CPS and antibodies, and (iii) masking of antibody by the capsule. The first aspect is probably important in situations involving limited amounts of antibody. The blocking of phagocytic receptors, especially those for IgG molecules, by immune complexes may also mediate resistance. Our evidence for this is that added cell-free CPS inhibited the opsonophagocytosis of salicylate-treated bacteria even when bacteria contained bound antibody, as determined by immunofluorescence. A similar phenomenon may occur with fully encapsulated bacteria, in that antibody-coated bacteria may bind to PMNL and then detach because of the loosely adherent nature of CPS. Thirdly, the capsule may act as a large antigenic sink, capable of absorbing large quantities of anticapsular antibody. Inhibiting capsule expression limits capsule shedding, allowing more antibodies to reach their intended targets, and may also unmask many of the antibodies attached to inner layers of the capsule. Much of the antibody fluorescence emanated from interior sections of the capsule, indicating that considerable quantities of IgG were masked below the capsule surface. Such antibodies may not be opsonic unless they are exposed on the bacterial surface.
With such a pronounced reduction of capsule by salicylate, perhaps other non-K opsonins may also play a role. Apparently, certain non-K antibodies are present in IVIG since the O1:K1 strain was opsonized after high-dose salicylate treatment of bacteria, even though the Kl serotype is not represented in this IVIG preparation. Apparently, antibodies directed at targets masked by the capsule (i.e., LPS) were present at low levels and became functional opsonins only after severe repression of CPS production (25) . After salicylate treatment of bacteria, IVIG not only became a better opsonin but also exhibited a broader range of activity. Thus, salicylate treatment may improve both efficiency and coverage in immunotherapy.
Whether salicylate actually inhibits capsule production in vivo is still not known. Preliminary data indicate that while salicylate allowed the reduction of the IVIG (Nosocuman) protective dose under certain conditions, the data were mixed. IVIG has been shown to protect mice against lethal K pneumoniae challenge (3, 4) . Mice challenged with K pneumoniae (25 50% lethal doses) received IVIG and salicylate at the time of challenge. At subtherapeutic levels of anti-K2 IgG, salicylate (-1 mM peak serum concentration) improved survival, perhaps by facilitating interaction between bacteria and host cells. However, at doses of IVIG capable of mediating protection, the addition of salicylate decreased survival, perhaps by altering an important host response. There are likely pleiotropic effects of salicylate on both host and target bacteria that are not well understood.
